Beam Therapeutics Inc. (BEAM): Price and Financial Metrics
BEAM Price/Volume Stats
Current price | $33.04 | 52-week high | $49.50 |
Prev. close | $33.96 | 52-week low | $16.95 |
Day low | $32.92 | Volume | 1,329,100 |
Day high | $34.17 | Avg. volume | 1,380,013 |
50-day MA | $32.23 | Dividend yield | N/A |
200-day MA | $27.90 | Market Cap | 2.70B |
BEAM Stock Price Chart Interactive Chart >
BEAM POWR Grades
- Momentum is the dimension where BEAM ranks best; there it ranks ahead of 27.6% of US stocks.
- BEAM's strongest trending metric is Stability; it's been moving down over the last 26 weeks.
- BEAM's current lowest rank is in the Sentiment metric (where it is better than 1.88% of US stocks).
BEAM Stock Summary
- BEAM's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 5,785.57 -- higher than 99.34% of US-listed equities with positive expected earnings growth.
- Of note is the ratio of BEAM THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; only 7.35% of US stocks have a lower such ratio.
- BEAM's price/sales ratio is 25.8; that's higher than the P/S ratio of 95.09% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to BEAM THERAPEUTICS INC are TNGX, DNLI, ALT, NRIX, and RPTX.
- Visit BEAM's SEC page to see the company's official filings. To visit the company's web site, go to www.beamtx.com.
BEAM Valuation Summary
- BEAM's price/earnings ratio is -7.1; this is 124.36% lower than that of the median Healthcare stock.
- Over the past 47 months, BEAM's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for BEAM.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
BEAM | 2023-12-29 | 27.2 | 2.8 | -7.1 | -7.1 |
BEAM | 2023-12-28 | 29.4 | 3.1 | -7.6 | -7.7 |
BEAM | 2023-12-27 | 29.1 | 3.0 | -7.6 | -7.6 |
BEAM | 2023-12-26 | 29.8 | 3.1 | -7.7 | -7.8 |
BEAM | 2023-12-22 | 29.5 | 3.1 | -7.7 | -7.7 |
BEAM | 2023-12-21 | 28.1 | 2.9 | -7.3 | -7.3 |
BEAM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BEAM has a Quality Grade of D, ranking ahead of 6.52% of graded US stocks.
- BEAM's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows BEAM's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0 | 1 | -0.966 |
2021-03-31 | 0 | 1 | -1.254 |
2020-12-31 | 0 | 1 | -1.054 |
2020-09-30 | 0 | 1 | -0.896 |
2019-12-31 | 0 | 1 | -1.360 |
BEAM Price Target
For more insight on analysts targets of BEAM, see our BEAM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $123.57 | Average Broker Recommendation | 1.36 (Strong Buy) |
Beam Therapeutics Inc. (BEAM) Company Bio
Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.
Latest BEAM News From Around the Web
Below are the latest news stories about BEAM THERAPEUTICS INC that investors may wish to consider to help them evaluate BEAM as an investment opportunity.
2 Cathie Wood Stocks That Could Soar in 2024, According to Wall StreetWall Street is uber-bullish on these two Ark Invest holdings. |
11 Most Promising Biotech Stocks to Buy According to AnalystsIn this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Most Promising Biotech Stocks to Buy According to Analysts. The biotech industry is making a resurgence […] |
The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeuticsbluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog. |
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of DirectorsCAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company’s board of directors. “Christi is an inspiring leader who knows firsthand what it takes to transform cutting-edge science into practice-changing commercial treatment options, most recently building and scaling the industry’s premier autologous cell therapy comp |
Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report?Beam Therapeutics Inc. (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
BEAM Price Returns
1-mo | -24.24% |
3-mo | 21.38% |
6-mo | 37.38% |
1-year | 9.59% |
3-year | -56.39% |
5-year | N/A |
YTD | 21.38% |
2023 | -30.40% |
2022 | -50.92% |
2021 | -2.39% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...